Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

Trial Profile

A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obeticholic acid (Primary) ; Fenofibrate; Ursodeoxycholic acid
  • Indications Primary biliary cirrhosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TARGET-PBC
  • Most Recent Events

    • 19 Sep 2019 Status changed from recruiting to active, no longer recruiting.
    • 14 May 2018 New trial record
    • 14 Apr 2018 Interim results (to date, n=311) assessing the safety and efficacy of obeticholic acid in patients with primary biliary cholangitis (PBC), presented at The International Liver Congress 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top